Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy

The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasingly common due to dramatic improvement in clinical outcomes of metabolic conditions. In this narrative review we introduce the preclinical data related to this receptor pathway and pancreatic ductal adenocarcinoma. Then, we summarize clinical data from postmarketting surveillance, randomized controlled trials, and observational studies. Lastly, we present considerations to accurately interpret these data and outline key knowledge gaps for further investigation.